Skip to content

Elite Pharmaceuticals, Inc.: 10-Q filed 2014-11-14

What Elite Pharmaceuticals, Inc. reported in its quarterly report filed 2014-11-14 (fiscal Q2 2015): 37 published measures, 108 facts as tagged in accession 0001144204-14-068797.

This filing

Form
10-Q (quarterly report)
Filed
2014-11-14
Fiscal period
fiscal Q2 2015
Accession
0001144204-14-068797 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Elite Pharmaceuticals, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2014-09-3023,889,159USD
At 2014-03-3124,317,722USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2014-09-3079,252,113USD
At 2014-03-31105,515,874USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2014-09-30-55,362,954USD
At 2014-03-31-81,198,152USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2014-09-307,627,078USD
At 2014-03-316,941,777USD
At 2013-09-30766,201USD
At 2013-03-31369,023USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2014-07-01 to 2014-09-3021,379,824USD92
2014-04-01 to 2014-09-3016,978,014USD183
2013-07-01 to 2013-09-30-9,637,513USD92
2013-04-01 to 2013-09-30-8,715,846USD183

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2014-09-30-208,028,632USD
At 2014-03-31-225,006,646USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2014-07-01 to 2014-09-30577,691,292shares92
2014-04-01 to 2014-09-30571,455,027shares183
2013-07-01 to 2013-09-30421,991,654shares92
2013-04-01 to 2013-09-30405,073,773shares183

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2014-07-01 to 2014-09-30739,869,496shares92
2014-04-01 to 2014-09-30733,633,231shares183
2013-07-01 to 2013-09-30421,991,654shares92
2013-04-01 to 2013-09-30405,073,773shares183

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2014-07-01 to 2014-09-300.04USD/shares92
2014-04-01 to 2014-09-300.03USD/shares183
2013-07-01 to 2013-09-30-0.02USD/shares92
2013-04-01 to 2013-09-30-0.02USD/shares183

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2014-07-01 to 2014-09-30-0.01USD/shares92
2014-04-01 to 2014-09-30-0.01USD/shares183
2013-07-01 to 2013-09-30-0.02USD/shares92
2013-04-01 to 2013-09-30-0.02USD/shares183

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2014-07-01 to 2014-09-300USD92
2014-04-01 to 2014-09-30-3,248USD183
2013-07-01 to 2013-09-302,269USD92
2013-04-01 to 2013-09-302,269USD183

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2014-09-305,167,376USD
At 2014-03-314,199,602USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2014-07-01 to 2014-09-30-4,061,337USD92
2014-04-01 to 2014-09-30-8,492,611USD183
2013-07-01 to 2013-09-30-686,580USD92
2013-04-01 to 2013-09-30-1,662,171USD183

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2014-09-3011,711,452USD
At 2014-03-319,924,763USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2014-07-01 to 2014-09-3070,075USD92
2014-04-01 to 2014-09-30148,281USD183
2013-07-01 to 2013-09-30255,945USD92
2013-04-01 to 2013-09-30330,723USD183

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2014-09-303,806,105USD
At 2014-03-316,160,824USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2014-09-301,097,784USD
At 2014-03-31732,076USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2014-07-01 to 2014-09-304,636,085USD92
2014-04-01 to 2014-09-309,500,511USD183
2013-07-01 to 2013-09-301,228,842USD92
2013-04-01 to 2013-09-302,347,109USD183

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2014-09-302,523,617USD
At 2014-03-311,932,486USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2014-07-01 to 2014-09-30574,748USD92
2014-04-01 to 2014-09-301,007,900USD183
2013-07-01 to 2013-09-30542,262USD92
2013-04-01 to 2013-09-30684,938USD183

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2014-07-01 to 2014-09-30681,669USD92
2014-04-01 to 2014-09-301,410,199USD183
2013-07-01 to 2013-09-30616,635USD92
2013-04-01 to 2013-09-301,195,647USD183

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2014-07-01 to 2014-09-303,565,181USD92
2014-04-01 to 2014-09-307,585,508USD183
2013-07-01 to 2013-09-30854,777USD92
2013-04-01 to 2013-09-301,424,268USD183

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2014-09-30591,652,031shares
At 2014-03-31560,142,430shares

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2014-09-30568,766USD
At 2014-03-31106,444USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2014-09-305,934,888USD
At 2014-03-315,508,377USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2014-09-306,358,470USD
At 2014-03-316,349,922USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2014-09-30651,861USD
At 2014-03-313,843,435USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2014-09-30381,249USD
At 2014-03-31131,144USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2014-09-30462,973USD
At 2014-03-31318,424USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2014-07-01 to 2014-09-3021,379,824USD92
2014-04-01 to 2014-09-3016,974,766USD183
2013-07-01 to 2013-09-30-9,635,244USD92
2013-04-01 to 2013-09-30-8,713,577USD183

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2014-07-01 to 2014-09-3021,379,824USD92
2014-04-01 to 2014-09-3016,978,014USD183
2013-07-01 to 2013-09-30-9,637,513USD92
2013-04-01 to 2013-09-30-8,715,846USD183

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2014-07-01 to 2014-09-30740,611USD92
2014-04-01 to 2014-09-301,367,164USD183
2013-07-01 to 2013-09-30272,561USD92
2013-04-01 to 2013-09-30649,018USD183

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2014-04-01 to 2014-09-30435,537USD183
2013-04-01 to 2013-09-30222,299USD183

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2014-07-01 to 2014-09-3025,441,161USD92
2014-04-01 to 2014-09-3025,467,377USD183
2013-07-01 to 2013-09-30-8,948,664USD92
2013-04-01 to 2013-09-30-7,051,406USD183

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2014-04-01 to 2014-09-306,227,485USD183
2013-04-01 to 2013-09-301,900,000USD183

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2014-04-01 to 2014-09-30365,708USD183
2013-04-01 to 2013-09-30-29,195USD183

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2014-04-01 to 2014-09-30591,130USD183
2013-04-01 to 2013-09-30361,527USD183

Inspect the source

Entity
Elite Pharmaceuticals, Inc. / CIK 0001053369
Captured
2026-09-20T05:17:33.154Z
SEC response SHA-256
b91e0331a01f96870ee44e841f605bd504e1bc784022b77f374cfe93dc363314

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001053369.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))